Pathogen-derived enzyme engineered for antibiotic design
The World Health Organization classified the drug-resistant pathogen Acinetobacter baumannii as a critical priority for antibiotic development. One development strategy targets the production of acinetobactin, the A. baumannii siderophore, or iron chelator, that allows the pathogen to scavenge for the scarce iron nutrient inside the host. Scientists have previously determined that synthetic analogs of acinetobactin can curb bacterial growth by blocking iron uptake or inhibiting acinetobactin formation. To aid in analog production, Syed Fardin Ahmed and Andrew Gulick at the University at Buffalo wanted to leverage A. baumannii enzymes that biosynthesize acinetobactin. They published their recent in the Journal of Biological Chemistry.

Acinetobactin biosynthesis involves an assembly line process performed by nonribosomal peptide synthetases. In these biosynthetic pathways, an adenylation domain plays a key role in substrate selectivity. The authors used available structures of the acinetobactin adenylation domain BasE to pinpoint residues to mutate in the substrate binding pocket to alter the size and allow for molecules larger than the natural substrate 2,3-dihydroxybenzoic acid. They performed enzyme activity assays and steady-state kinetic analysis to identify and characterize four BasE variants that functioned with larger substrates with efficiencies similar to the wild-type enzyme with the natural substrate.
Finally, the researchers solved the structures of three BasE variants with alternative substrates in the binding pockets. These structures confirmed visually that the mutations enlarged the binding pockets, highlighting which BasE residues contribute to accommodating specific portions of the substrate chemical structure.
Future steps will include completing a combined chemical and enzymatic synthesis of acinetobactin analogs and testing their activity for bacterial growth inhibition. The authors anticipate that their detailed investigation of BasE substrate selectivity will advance the discovery of siderophore-inspired antibiotics.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Top reviewers at ASBMB journals
Editors recognize the heavy-lifters and rising stars during Peer Review Week.

Teaching AI to listen
A computational medicine graduate student reflects on building natural language processing tools that extract meaning from messy clinical notes — transforming how we identify genetic risk while redefining what it means to listen in science.

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.

How sugars shape Marfan syndrome
Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.